Madrigal Pharmaceuticals, Inc.
MDGL
$424.00
$11.772.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 55.05% | 32.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 55.05% | 32.84% | |||
| Cost of Revenue | 100.86% | 31.00% | |||
| Gross Profit | 53.49% | 32.90% | |||
| SG&A Expenses | 17.26% | 18.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.06% | 27.15% | |||
| Operating Income | 40.48% | -18.38% | |||
| Income Before Tax | 42.27% | -23.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.27% | -23.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.27% | -23.26% | |||
| EBIT | 40.48% | -18.38% | |||
| EBITDA | 40.68% | -18.46% | |||
| EPS Basic | 42.57% | -22.36% | |||
| Normalized Basic EPS | 42.57% | -22.36% | |||
| EPS Diluted | 42.57% | -22.36% | |||
| Normalized Diluted EPS | 42.57% | -22.36% | |||
| Average Basic Shares Outstanding | 0.52% | 0.74% | |||
| Average Diluted Shares Outstanding | 0.52% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||